“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial”, J of Skin, vol. 7, no. 2, p. s117, Mar. 2023, doi: 10.25251/skin.7.supp.117.